Drugs / SHR4597
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06385964 | May 2024 → Feb 2025 | asthma | Guangdong Hengrui Pharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06940700 | Apr → Oct 2025 overdue | asthma | Guangdong Hengrui Pharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SHR-4597 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06385964 ↗ |
| Route | Inhaled | “SHR-4597 by dry powder inhalation” NCT06385964 ↗ |